Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening

Jeffrey W. Tyner, Wayne F. Yang, Armand Bankhead, Guang Fan, Luke B. Fletcher, Jade Bryant, Jason M. Glover, Bill H. Chang, Stephen E. Spurgeon, William H. Fleming, Tibor Kovacsovics, Jason R. Gotlib, Stephen T. Oh, Michael W. Deininger, Christian Michel Zwaan, Monique L. Den Boer, Marry M. Van Den Heuvel-Eibrink, Thomas O'Hare, Brian J. Druker, Marc M. Loriaux

Research output: Contribution to journalArticle

93 Scopus citations

Abstract

Kinases are dysregulated in most cancers, but the frequency of specific kinase mutations is low, indicating a complex etiology in kinase dysregulation. Here, we report a strategy to rapidly identify functionally important kinase targets, irrespective of the etiology of kinase pathway dysregulation, ultimately enabling a correlation of patient genetic profiles to clinically effective kinase inhibitors. Our methodology assessed the sensitivity of primary leukemia patient samples to a panel of 66 small-molecule kinase inhibitors over 3 days. Screening of 151 leukemia patient samples revealed a wide diversity of drug sensitivities, with 70% of the clinical specimens exhibiting hypersensitivity to one or more drugs. From this data set, we developed an algorithm to predict kinase pathway dependence based on analysis of inhibitor sensitivity patterns. Applying this algorithm correctly identified pathway dependence in proof-of-principle specimens with known oncogenes, including a rare FLT3 mutation outside regions covered by standard molecular diagnostic tests. Interrogation of all 151 patient specimens with this algorithm identified a diversity of kinase targets and signaling pathways that could aid prioritization of deep sequencing data sets, permitting a cumulative analysis to understand kinase pathway dependence within leukemia subsets. In a proof-of-principle case, we showed that in vitro drug sensitivity could predict both a clinical response and the development of drug resistance. Taken together, our results suggested that drug target scores derived from a comprehensive kinase inhibitor panel could predict pathway dependence in cancer cells while simultaneously identifying potential therapeutic options.

Original languageEnglish
Pages (from-to)285-296
Number of pages12
JournalCancer research
Volume73
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint Dive into the research topics of 'Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening'. Together they form a unique fingerprint.

  • Cite this

    Tyner, J. W., Yang, W. F., Bankhead, A., Fan, G., Fletcher, L. B., Bryant, J., Glover, J. M., Chang, B. H., Spurgeon, S. E., Fleming, W. H., Kovacsovics, T., Gotlib, J. R., Oh, S. T., Deininger, M. W., Zwaan, C. M., Den Boer, M. L., Van Den Heuvel-Eibrink, M. M., O'Hare, T., Druker, B. J., & Loriaux, M. M. (2013). Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer research, 73(1), 285-296. https://doi.org/10.1158/0008-5472.CAN-12-1906